Controlled clinical trials of moxifloxacin in old patients with community-acquired pneumonia
Abstract
Objective To evaluate the efficiency and safety of moxifloxacin in old patients with community-acquired pneumonia (CAP). Methods A prospective design was conducted. 100 old patients with CAP were randomly divided into trial group and control group. The 52 trial group members were treated with moxifloxacin administering 0.4 g, po,qd for 14 d. In the control group, 43 patients were treated with ceforuxime injection administering 2.5 g, iv, bid and clalithromycin 0.25 g, po,bid for 14 d. Statistical difference was analyzed in terms effectiveness, side effects and compliance and the comparisons were made between the groups. Results After treatment, the total cured rate for the trail group was 87%, while for the control group it was 88%:P0.05. However, the group difference in the cured rates on d 3 and d 5 were significant (P0.05) in favor of the trial group. The clinical sign symptom such as fever,cough and chest pain in the trail group were alleviated significantly earlier than that in the control group(P values ranged between less than 0.01 and less than 0.05). A few side effects cause by moxifloxacin were recorded. Specific pathogens of CAP could only be found in 27.9% of the patients. Conclusions Moxifloxacin is effective , safe and convenient in use for old patients with CAP.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.